A Randomised, Double-blinded, Single-dose, Dose-escalation, First Human Dose Trial Investigating Safety, Tolerability and Pharmacokinetics of NNC0194-0499 in Male Subjects With Overweight or Obesity
Phase of Trial: Phase I
Latest Information Update: 01 Nov 2017
At a glance
- Drugs NNC0194 0499 (Primary)
- Indications Obesity
- Focus Adverse reactions; First in man
- Sponsors Novo Nordisk
- 27 Oct 2017 Status changed from active, no longer recruiting to completed.
- 26 Sep 2017 Planned primary completion date changed from 2 Oct 2017 to 26 Oct 2017.
- 26 Sep 2017 Status changed from recruiting to active, no longer recruiting.